viewBiocept Inc

Biocept says it has received more than 50,000 COVID-19 specimens for processing at its San Diego lab

Its growing list of clients for COVID-19 testing includes hospitals, clinics, skilled nursing facilities, corporate clients and athletic facilities

The company also is reporting progress with COVID-19 specimen collection kits

Biocept Inc (NASDAQ:BIOC) announced Tuesday that it has received more than 50,000 COVID-19 specimens to date for processing through its RT-PCR technology at its San Diego lab.

"We have continued to gain momentum in testing COVID-19 specimens while maintaining a standard of providing the vast majority of COVID-19 test results to our healthcare provider customers within 48 hours of receiving a sample," said CEO Michael Nall in a statement. "I am proud of our team for working hard to scale our business in a short time to handle this rapidly increasing volume."

Biocept said its growing list of clients for COVID-19 testing includes hospitals, clinics, skilled nursing facilities, corporate clients, and athletic facilities.

READ: Biocept's Target Selector outperforms traditional tumor cell detection test in metastatic lung cancer study

The company is also reporting progress with its internally developed COVID-19 specimen collection kits. 

Biocept said it has received verification from a contract research organization (CRO) of the viricidal effects of the specimen collection tube used for shipping patient samples, adding that this is an important gating factor prior to the adoption of the internally developed kits. 

The Biocept-developed COVID-19 specimen collection kit will now be validated as part of the company's COVID-19 workflow in its lab prior to being sent to the US Food and Drug Administration for Emergency Use Authorization review. 

Biocept said it remains on track for launching the Biocept-developed specimen collection kits later this year for use in its lab and for potential sales to other labs.

Biocept’s lab is high-complexity, CLIA-certified and CAP-accredited with a BSL-2 safety level. Its specialized, licensed molecular lab staff have been trained in performing the COVID-19 testing.

Contact the author: [email protected]

Follow him on Twitter @PatrickMGraham

Quick facts: Biocept Inc

Price: 4.44 USD

Market: NASDAQ
Market Cap: $59.48 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Biocept Inc named herein, including the promotion by the Company of Biocept Inc in any Content on the Site, the Company receives from said...


Biocept reveals $6.6M in top-line growth for 3Q driven by coronavirus RT-PCR...

Biocept Inc (NASDAQ:BIOC) (FRA:B003) CEO Mike Nall, CFO Tim Kennedy, and Chief Medical Officer Dr Michael Dugan joined Proactive to discuss the group's third-quarter results that saw its revenue jump four-fold year-over-year, driven by the molecular diagnostics company’s astute decision to offer...

1 week, 2 days ago

2 min read